{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T17:57:34Z","timestamp":1709920654074},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.cger.2005.06.004","type":"journal-article","created":{"date-parts":[[2005,9,22]],"date-time":"2005-09-22T07:21:26Z","timestamp":1127373686000},"page":"735-746","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacologic Agents for the Treatment of Obesity"],"prefix":"10.1016","volume":"21","author":[{"given":"Monica","family":"Mathys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2005.06.004_bib1","unstructured":"CDC, National Center for Health Statistics, National Health and Nutrition Examination Survey. Health, United States (Table 70); 2002"},{"issue":"17","key":"10.1016\/j.cger.2005.06.004_bib2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1001\/archinte.158.17.1855","article-title":"Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults","volume":"158","year":"1998","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.cger.2005.06.004_bib3","first-page":"44","article-title":"Treatment of obesity in the elderly patient","volume":"10","author":"Mathys","year":"2002","journal-title":"Clinical Geriatrics"},{"key":"10.1016\/j.cger.2005.06.004_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archinte.163.9.1046","article-title":"National trends in antiobesity medication use","volume":"163","author":"Stafford","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cger.2005.06.004_bib5","series-title":"AHFS drug information (online)","article-title":"Phentermine","year":"2004"},{"key":"10.1016\/j.cger.2005.06.004_bib6","series-title":"AHFS drug information (online)","article-title":"Sibutramine","year":"2004"},{"key":"10.1016\/j.cger.2005.06.004_bib7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1345\/aph.18319","article-title":"Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity","volume":"33","author":"Luque","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cger.2005.06.004_bib8","series-title":"Lexi-Comp's drug information handbook","article-title":"Sibutramine","year":"2003"},{"key":"10.1016\/j.cger.2005.06.004_bib9","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cger.2005.06.004_bib10","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomized trial","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cger.2005.06.004_bib11","first-page":"505","article-title":"Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity","volume":"50","year":"2001","journal-title":"J Fam Pract"},{"key":"10.1016\/j.cger.2005.06.004_bib12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","article-title":"Benefits of lifestyle modification in the pharmacologic treatment of obesity","volume":"161","author":"Wadden","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cger.2005.06.004_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1067\/mhj.2001.117510","article-title":"Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia","volume":"142","author":"Dujovne","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2005.06.004_bib14","series-title":"AHFS drug information (online)","article-title":"Orlistat","year":"2004"},{"issue":"9","key":"10.1016\/j.cger.2005.06.004_bib15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/009127002401102939","article-title":"Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects","volume":"42","author":"Zhi","year":"2002","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.cger.2005.06.004_bib16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1345\/aph.1C122","article-title":"Orlistat enhances warfarin effect","volume":"37","author":"MacWalter","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cger.2005.06.004_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJM200004133421518","article-title":"Reduction in blood cyclosporine concentrations by orlistat","volume":"342","author":"Colman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cger.2005.06.004_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"Xenical in the prevention of diabetes in obese subjects (XENDOS) study","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2005.06.004_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.06.004_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davison","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2005.06.004_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Arch Fam Med"},{"issue":"6","key":"10.1016\/j.cger.2005.06.004_bib22","first-page":"505","article-title":"Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith","year":"2001","journal-title":"J Fam Pract"},{"key":"10.1016\/j.cger.2005.06.004_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2005.06.004_bib24","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.cger.2005.06.004_bib25","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2005.06.004_bib26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes","volume":"25","author":"Kelly","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2005.06.004_bib27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat on overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2005.06.004_bib28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/001857879903401009","article-title":"Orlistat","volume":"34","author":"Cada","year":"1999","journal-title":"Hosp Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.cger.2005.06.004_bib29","first-page":"26","article-title":"Weight loss efficacy of orlistat in obese elderly adults","volume":"7","author":"Segal","year":"1999","journal-title":"J Obes Research"},{"issue":"11","key":"10.1016\/j.cger.2005.06.004_bib30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s002280050565","article-title":"Sibutramine pharmacokinetics in young and elderly healthy subjects","volume":"54","author":"Hind","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cger.2005.06.004_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000047310","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients","volume":"94","author":"Hazenberg","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.cger.2005.06.004_bib32","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2337\/diacare.24.11.1957","article-title":"Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control","volume":"24","author":"Gockel","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cger.2005.06.004_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study","volume":"248","author":"Lindgarde","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.cger.2005.06.004_bib34","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0002-9149(03)00112-7","article-title":"Effect of orlistat added to diet (30% of calories from fat) on plasma, lipids, glucose, and insulin in obese patients with hypercholesterolemia","volume":"91","author":"Lucas","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069005000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069005000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T12:32:35Z","timestamp":1553517155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069005000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0749069005000479"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2005.06.004","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}